Related Experiment Video
Updated: Jan 26, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Nkx-2.5 Regulates MDR1 Expression via Its Upstream Promoter in Breast Cancer Cells
Jung-Suk Lim1, Gyu Yeon Jung1, Seung-Yoon Park1
1Department of Biochemistry, School of Medicine, Dongguk University, Gyeongju, Korea.
Background:
Increased expression of MDR1 gene is one of the major mechanisms responsible for multidrug resistance in cancer cells. Two alternative promoters, upstream and downstream, are responsible for transcription of MDR1 gene in the human. However, the molecular mechanism regarding the transactivation of MDR1 upstream promoter (USP) has not been determined.
Methods:
Dual-luciferase reporter gene assays were used to assess the effect of Nkx-2.5 on MDR1 USP activity using reporter plasmids for human MDR1 USP and its mutants. MDR1 mRNA level was examined by quantitative real-time PCR. The direct binding of Nkx-2.5 to the USP of MDR1 was evaluated by promoter enzyme immunoassays and chromatin immunoprecipitation assays.
Results:
Nkx-2.5 significantly stimulates the transactivation of MDR1 USP and increases MDR1 mRNA expression in MCF7 breast cancer cells. Reporter gene assays with deleted MDR1 USPs showed that the Nkx-2.5-binding site is located between positions -71 and +12. Mutation of the Nkx-2.5-binding site at nucleotide +4 to +10 markedly reduced the Nkx-2.5-mediated activation of MDR1 USP activity. A promoter binding immunoassay and a chromatin immunoprecipitation assay revealed that Nkx-2.5 binds directly to the region +4/+10 of human MDR1 USP.
Conclusion:
The results in the present study show Nkx-2.5 is a positive regulator for the transactivation of MDR1 USP in MCF7 breast cancer cells. Our findings will help elucidate the regulatory mechanism responsible for the multidrug resistant cancer phenotype.
Insights
The transcription factor Nkx-2.5 activates the MDR1 upstream promoter (USP), increasing multidrug resistance gene expression in breast cancer cells. This identifies Nkx-2.5 as a key regulator in cancer multidrug resistance.
Area of Science:
- Molecular biology
- Cancer research
- Gene regulation
Background:
- Multidrug resistance (MDR) in cancer is often mediated by increased MDR1 gene expression.
- The MDR1 gene has two promoters: upstream and downstream.
- The molecular mechanisms regulating the MDR1 upstream promoter (USP) remain largely unknown.
Purpose of the Study:
- To investigate the role of Nkx-2.5 in the transactivation of the MDR1 USP.
- To identify the specific binding site of Nkx-2.5 on the MDR1 USP.
Main Methods:
- Dual-luciferase reporter gene assays were used to assess MDR1 USP activity.
- Quantitative real-time PCR measured MDR1 mRNA levels.
- Promoter enzyme immunoassays and chromatin immunoprecipitation assays confirmed Nkx-2.5 binding to the MDR1 USP.
Main Results:
- Nkx-2.5 significantly enhanced MDR1 USP activity and increased MDR1 mRNA expression in MCF7 breast cancer cells.
- The Nkx-2.5 binding site was localized to the region between -71 and +12 of the MDR1 USP.
- Mutation of the Nkx-2.5 binding site (+4 to +10) reduced Nkx-2.5-mediated activation, and direct binding was confirmed.
Conclusions:
- Nkx-2.5 acts as a positive regulator for MDR1 USP transactivation in MCF7 breast cancer cells.
- These findings contribute to understanding the regulatory mechanisms underlying the multidrug-resistant cancer phenotype.
Related Concept Videos
The Eukaryotic Promoter Region
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
Regulation of Expression Occurs at Multiple Steps
Regulation of Expression at Multiple Steps
Constitutive and Regulated Gene Expression
Master Transcription Regulators

